Longitudinal decline of diffusing capacity of the lung for carbon monoxide in community subjects with the PiMZ α1-antitrypsin phenotype

Graciela Emilia Silva Torres, Stefano Guerra, Samuel M Keim, Robert A. Barbee, Duane L Sherrill

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: It is well known that homozygous deficiency of α2-antitrypsin, PiZZ, is associated with an increased risk of emphysema. However, studies evaluating associations between the heterozygous form PiMZ with emphysema and impaired lung function have provided conflicting results. Study objective: The goal of this study was to determine if the phenotype PiMZ is associated with an accelerated decline in diffusing capacity of the lung for carbon monoxide (DLCO). Design and methods: The Tucson Epidemiologic Study of Airway Obstructive Disease is a prospective, population-based cohort study initiated in 1972. Participants completed standardized questionnaires in up to 12 periodic surveys and DLCO assessments in up to 4 surveys. Random-effects models were used to determine the effects of α1-antitrypsin phenotypes on percentage of predicted (% predicted) DLCO levels among 1,075 subjects ≥ 18 years old. Results: % predicted DLCO declined more rapidly in subjects who smoked compared to nonsmoking subjects. Additionally, in smokers, the PiMZ phenotype was associated with borderline % predicted DLCO deficits at age 40 years (8.6%; p = 0.075) and significant % predicted DLCO deficits at age 60 years (15.2%; p = 0.001) and 80 years (21.9%; p = 0.003), as compared with the PiMM phenotype. Conclusions: DLCO may be a more sensitive indicator of the long-term effects of intermediate levels of α1-antitrypsin on lung function especially in subjects who smoke.

Original languageEnglish (US)
Pages (from-to)1095-1100
Number of pages6
JournalChest
Volume133
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Lung Volume Measurements
Carbon Monoxide
Phenotype
Emphysema
Lung
Smoke
Epidemiologic Studies
Cohort Studies
Population
Surveys and Questionnaires

Keywords

  • α-antitrypsin deficiency
  • Antitrypsin
  • Pulmonary epidemiology

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Longitudinal decline of diffusing capacity of the lung for carbon monoxide in community subjects with the PiMZ α1-antitrypsin phenotype. / Silva Torres, Graciela Emilia; Guerra, Stefano; Keim, Samuel M; Barbee, Robert A.; Sherrill, Duane L.

In: Chest, Vol. 133, No. 5, 05.2008, p. 1095-1100.

Research output: Contribution to journalArticle

@article{6d742cb810954b8b8e2c40856a228b65,
title = "Longitudinal decline of diffusing capacity of the lung for carbon monoxide in community subjects with the PiMZ α1-antitrypsin phenotype",
abstract = "Background: It is well known that homozygous deficiency of α2-antitrypsin, PiZZ, is associated with an increased risk of emphysema. However, studies evaluating associations between the heterozygous form PiMZ with emphysema and impaired lung function have provided conflicting results. Study objective: The goal of this study was to determine if the phenotype PiMZ is associated with an accelerated decline in diffusing capacity of the lung for carbon monoxide (DLCO). Design and methods: The Tucson Epidemiologic Study of Airway Obstructive Disease is a prospective, population-based cohort study initiated in 1972. Participants completed standardized questionnaires in up to 12 periodic surveys and DLCO assessments in up to 4 surveys. Random-effects models were used to determine the effects of α1-antitrypsin phenotypes on percentage of predicted ({\%} predicted) DLCO levels among 1,075 subjects ≥ 18 years old. Results: {\%} predicted DLCO declined more rapidly in subjects who smoked compared to nonsmoking subjects. Additionally, in smokers, the PiMZ phenotype was associated with borderline {\%} predicted DLCO deficits at age 40 years (8.6{\%}; p = 0.075) and significant {\%} predicted DLCO deficits at age 60 years (15.2{\%}; p = 0.001) and 80 years (21.9{\%}; p = 0.003), as compared with the PiMM phenotype. Conclusions: DLCO may be a more sensitive indicator of the long-term effects of intermediate levels of α1-antitrypsin on lung function especially in subjects who smoke.",
keywords = "α-antitrypsin deficiency, Antitrypsin, Pulmonary epidemiology",
author = "{Silva Torres}, {Graciela Emilia} and Stefano Guerra and Keim, {Samuel M} and Barbee, {Robert A.} and Sherrill, {Duane L}",
year = "2008",
month = "5",
doi = "10.1378/chest.07-2405",
language = "English (US)",
volume = "133",
pages = "1095--1100",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "5",

}

TY - JOUR

T1 - Longitudinal decline of diffusing capacity of the lung for carbon monoxide in community subjects with the PiMZ α1-antitrypsin phenotype

AU - Silva Torres, Graciela Emilia

AU - Guerra, Stefano

AU - Keim, Samuel M

AU - Barbee, Robert A.

AU - Sherrill, Duane L

PY - 2008/5

Y1 - 2008/5

N2 - Background: It is well known that homozygous deficiency of α2-antitrypsin, PiZZ, is associated with an increased risk of emphysema. However, studies evaluating associations between the heterozygous form PiMZ with emphysema and impaired lung function have provided conflicting results. Study objective: The goal of this study was to determine if the phenotype PiMZ is associated with an accelerated decline in diffusing capacity of the lung for carbon monoxide (DLCO). Design and methods: The Tucson Epidemiologic Study of Airway Obstructive Disease is a prospective, population-based cohort study initiated in 1972. Participants completed standardized questionnaires in up to 12 periodic surveys and DLCO assessments in up to 4 surveys. Random-effects models were used to determine the effects of α1-antitrypsin phenotypes on percentage of predicted (% predicted) DLCO levels among 1,075 subjects ≥ 18 years old. Results: % predicted DLCO declined more rapidly in subjects who smoked compared to nonsmoking subjects. Additionally, in smokers, the PiMZ phenotype was associated with borderline % predicted DLCO deficits at age 40 years (8.6%; p = 0.075) and significant % predicted DLCO deficits at age 60 years (15.2%; p = 0.001) and 80 years (21.9%; p = 0.003), as compared with the PiMM phenotype. Conclusions: DLCO may be a more sensitive indicator of the long-term effects of intermediate levels of α1-antitrypsin on lung function especially in subjects who smoke.

AB - Background: It is well known that homozygous deficiency of α2-antitrypsin, PiZZ, is associated with an increased risk of emphysema. However, studies evaluating associations between the heterozygous form PiMZ with emphysema and impaired lung function have provided conflicting results. Study objective: The goal of this study was to determine if the phenotype PiMZ is associated with an accelerated decline in diffusing capacity of the lung for carbon monoxide (DLCO). Design and methods: The Tucson Epidemiologic Study of Airway Obstructive Disease is a prospective, population-based cohort study initiated in 1972. Participants completed standardized questionnaires in up to 12 periodic surveys and DLCO assessments in up to 4 surveys. Random-effects models were used to determine the effects of α1-antitrypsin phenotypes on percentage of predicted (% predicted) DLCO levels among 1,075 subjects ≥ 18 years old. Results: % predicted DLCO declined more rapidly in subjects who smoked compared to nonsmoking subjects. Additionally, in smokers, the PiMZ phenotype was associated with borderline % predicted DLCO deficits at age 40 years (8.6%; p = 0.075) and significant % predicted DLCO deficits at age 60 years (15.2%; p = 0.001) and 80 years (21.9%; p = 0.003), as compared with the PiMM phenotype. Conclusions: DLCO may be a more sensitive indicator of the long-term effects of intermediate levels of α1-antitrypsin on lung function especially in subjects who smoke.

KW - α-antitrypsin deficiency

KW - Antitrypsin

KW - Pulmonary epidemiology

UR - http://www.scopus.com/inward/record.url?scp=43649094201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43649094201&partnerID=8YFLogxK

U2 - 10.1378/chest.07-2405

DO - 10.1378/chest.07-2405

M3 - Article

C2 - 18263681

AN - SCOPUS:43649094201

VL - 133

SP - 1095

EP - 1100

JO - Chest

JF - Chest

SN - 0012-3692

IS - 5

ER -